{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T18:04:13Z","timestamp":1789149853809,"version":"build-2803163510"},"reference-count":59,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice &amp; Research Clinical Rheumatology"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.berh.2023.101873","type":"journal-article","created":{"date-parts":[[2023,11,11]],"date-time":"2023-11-11T07:54:39Z","timestamp":1699689279000},"page":"101873","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Systemic lupus erythematosus and glucocorticoids: A never-ending story?"],"prefix":"10.1016","volume":"37","author":[{"given":"Diana","family":"Paredes-Ruiz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7788-1043","authenticated-orcid":false,"given":"Guillermo","family":"Ruiz-Irastorza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahir","family":"Amoura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.berh.2023.101873_bib1","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1136\/annrheumdis-2019-215089","article-title":"Update of the EULAR recommendations for the management of systemic lupus erythematosus","volume":"78","author":"Fanouriakis","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2023.101873_bib2","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1136\/ard.8.2.97","article-title":"Adrenocortical hormone in arthritis : preliminary report","volume":"8","author":"Hench","year":"1949","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2023.101873_bib3","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1093\/rheumatology\/keu148","article-title":"Glucocorticoids and irreversible damage in patients with systemic lupus erythematosus","volume":"53","author":"Ruiz-Arruza","year":"2014","journal-title":"Rheumatology"},{"key":"10.1016\/j.berh.2023.101873_bib4","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1177\/0961203320930099","article-title":"Seventy years after Hench's Nobel prize: revisiting the use of glucocorticoids in systemic lupus erythematosus","volume":"29","author":"Ruiz-Irastorza","year":"2020","journal-title":"Lupus"},{"key":"10.1016\/j.berh.2023.101873_bib5","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2022-000864","article-title":"Generic and disease-adapted cardiovascular risk scores as predictors of atherosclerosis progression in SLE","volume":"10","author":"Panopoulos","year":"2023","journal-title":"Lupus Sci Med"},{"key":"10.1016\/j.berh.2023.101873_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/lupus-2021-000590","article-title":"Impact of glucocorticoids on the incidence of lupus-related major organ damage: a systematic literature review and meta-regression analysis of longitudinal observational studies","volume":"8","author":"Ugarte-Gil","year":"2021","journal-title":"Lupus Sci Med"},{"key":"10.1016\/j.berh.2023.101873_bib7","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1177\/09612033221093485","article-title":"Prednisone and long-term damage in systemic lupus erythematosus: which is the threshold dose? A pilot study","volume":"31","author":"Danza","year":"2022","journal-title":"Lupus"},{"key":"10.1016\/j.berh.2023.101873_bib8","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1002\/1529-0131(199805)41:5<761::AID-ART2>3.0.CO;2-M","article-title":"A new hypothesis of modular glucocorticoid actions: steroid treatment of rheumatic diseases revisited","volume":"41","author":"Buttgereit","year":"1998","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2023.101873_bib9","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S0039-128X(01)00171-4","article-title":"Rapid glucocorticoid effects on immune cells","volume":"67","author":"Buttgereit","year":"2002","journal-title":"Steroids"},{"key":"10.1016\/j.berh.2023.101873_bib10","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMra050541","article-title":"Antiinflammatory action of glucocorticoids \u2014 new mechanisms for old drugs","volume":"353","author":"Rhen","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.berh.2023.101873_bib11","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.yfrne.2017.05.001","article-title":"Checks and balances: the glucocorticoid receptor and NF\u0138B in good times and bad","volume":"46","author":"Bekhbat","year":"2017","journal-title":"Front Neuroendocrinol"},{"key":"10.1016\/j.berh.2023.101873_bib12","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.mce.2013.01.026","article-title":"Optimized glucocorticoid therapy: teaching old drugs new tricks","volume":"380","author":"Strehl","year":"2013","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.berh.2023.101873_bib13","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.tem.2012.11.005","article-title":"The five Rs of glucocorticoid action during inflammation: ready, reinforce, repress, resolve, and restore","volume":"24","author":"Busillo","year":"2013","journal-title":"Trends Endocrinol Metabol"},{"key":"10.1016\/j.berh.2023.101873_bib14","doi-asserted-by":"crossref","first-page":"3408","DOI":"10.1002\/art.20583","article-title":"Glucocorticoids in the treatment of rheumatic diseases: an update on the mechanisms of action","volume":"50","author":"Buttgereit","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2023.101873_bib15","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/nrm1009","article-title":"Nongenomic actions of steroid hormones","volume":"4","author":"L\u00f6sel","year":"2003","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.berh.2023.101873_bib16","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1513\/pats.200402-015MS","article-title":"Post-transcriptional and nongenomic effects of glucocorticoids","volume":"1","author":"Stellato","year":"2004","journal-title":"Proc Am Thorac Soc"},{"key":"10.1016\/j.berh.2023.101873_bib17","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0140-6736(00)02463-6","article-title":"Therapeutic implications of non-genomic glucocorticoid activity","volume":"356","author":"Lipworth","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.berh.2023.101873_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/nyas.12364","article-title":"Unraveling the functions of the membrane-bound glucocorticoid receptors: first clues on origin and functional activity","volume":"1318","author":"Strehl","year":"2014","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.berh.2023.101873_bib19","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1191\/0961203302lu243oa","article-title":"Low-dose pulse methylprednisolone for systemic lupus erythematosus flares is efficacious and has a decreased risk of infectious complications","volume":"11","author":"Badsha","year":"2002","journal-title":"Lupus"},{"key":"10.1016\/j.berh.2023.101873_bib20","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1177\/0961203318768888","article-title":"Intravenous pulses of methylprednisolone to treat flares of immune-mediated diseases: how much, how long?","volume":"27","author":"Danza","year":"2018","journal-title":"Lupus"},{"key":"10.1016\/j.berh.2023.101873_bib21","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1023\/A:1026445108136","article-title":"Bioenergetics of human peripheral blood mononuclear cell metabolism in quiescent, activated, and glucocorticoid-treated states","volume":"20","author":"Schmid","year":"2000","journal-title":"Biosci Rep"},{"key":"10.1016\/j.berh.2023.101873_bib22","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1002\/acr.23322","article-title":"Restrictive use of oral glucocorticoids in systemic lupus erythematosus and prevention of damage without worsening long-term disease control: an observational study","volume":"70","author":"Ruiz-Arruza","year":"2018","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.berh.2023.101873_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2019.102359","article-title":"Prolonged remission in SLE is possible by using reduced doses of prednisone: an observational study from the Lupus-Cruces and Lupus-Bordeaux inception cohorts","volume":"18","author":"Ruiz-Irastorza","year":"2019","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.berh.2023.101873_bib24","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1136\/annrheumdis-2012-202844","article-title":"Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids","volume":"72","author":"Condon","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2023.101873_bib25","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1177\/0961203311418269","article-title":"Efficacy and safety of enteric-coated mycophenolate sodium in combination with two glucocorticoid regimens for the treatment of active lupus nephritis","volume":"20","author":"Zeher","year":"2011","journal-title":"Lupus"},{"key":"10.1016\/j.berh.2023.101873_bib26","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.kint.2018.08.025","article-title":"A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis","volume":"95","author":"Rovin","year":"2019","journal-title":"Kidney Int"},{"key":"10.1016\/j.berh.2023.101873_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2021.102898","article-title":"Eurolupus cyclophosphamide plus repeated pulses of methyl-prednisolone for the induction therapy of class III, IV and V lupus nephritis","volume":"20","author":"Ruiz-Irastorza","year":"2021","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.berh.2023.101873_bib28","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.autrev.2017.11.002","article-title":"Can we manage lupus nephritis without chronic corticosteroids administration?","volume":"17","author":"Lightstone","year":"2018","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.berh.2023.101873_bib29","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2016-000173","article-title":"Clinicians approaches to management of background treatment in patients with SLE in clinical remission: results of an international observational survey","volume":"4","author":"Ngamjanyaporn","year":"2017","journal-title":"Lupus Sci Med"},{"key":"10.1016\/j.berh.2023.101873_bib30","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1136\/annrheumdis-2019-216303","article-title":"Withdrawal of low-dose prednisone in SLE patients with a clinically quiescent disease for more than 1 year: a randomised clinical trial","volume":"79","author":"Mathian","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2023.101873_bib31","doi-asserted-by":"crossref","first-page":"5517","DOI":"10.1093\/rheumatology\/keab149","article-title":"Low-dose glucocorticoids should be withdrawn or continued in systemic lupus erythematosus? A systematic review and meta-analysis on risk of flare and damage accrual","volume":"60","author":"Ji","year":"2021","journal-title":"Rheumatology"},{"key":"10.1016\/j.berh.2023.101873_bib32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/lupus-2021-000603","article-title":"Risk factors of flare in patients with systemic lupus erythematosus after glucocorticoids withdrawal. A systematic review and meta-analysis","volume":"9","author":"Ji","year":"2022","journal-title":"Lupus Sci Med"},{"key":"10.1016\/j.berh.2023.101873_bib33","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1177\/09612033211002269","article-title":"Which patients with systemic lupus erythematosus in remission can withdraw low dose steroids? Results from a single inception cohort study","volume":"30","author":"Fasano","year":"2021","journal-title":"Lupus"},{"key":"10.1016\/j.berh.2023.101873_bib34","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1093\/rheumatology\/keac225","article-title":"Low-dose glucocorticoids withdrawn in systemic lupus erythematosus: a desirable and attainable goal","volume":"62","author":"Ji","year":"2022","journal-title":"Rheumatology"},{"key":"10.1016\/j.berh.2023.101873_bib35","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1093\/ndt\/gfk073","article-title":"Withdrawal of therapy in patients with proliferative lupus nephritis: long-term follow-up","volume":"21","author":"Moroni","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.berh.2023.101873_bib36","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1136\/annrheumdis-2015-208916","article-title":"Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force","volume":"75","author":"Strehl","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2023.101873_bib37","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1002\/acr2.11267","article-title":"Gradual glucocorticosteroid withdrawal is safe in clinically quiescent systemic lupus erythematosus","volume":"3","author":"Tselios","year":"2021","journal-title":"ACR Open Rheumatol"},{"key":"10.1016\/j.berh.2023.101873_bib38","doi-asserted-by":"crossref","first-page":"5489","DOI":"10.1093\/rheumatology\/keab347","article-title":"Prednisone in systemic lupus erythematosus: taper quickly, withdraw slowly","volume":"60","author":"Ruiz-Irastorza","year":"2021","journal-title":"Rheumatology"},{"key":"10.1016\/j.berh.2023.101873_bib39","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1001\/jamaophthalmol.2014.3459","article-title":"The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy","volume":"132","author":"Melles","year":"2014","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.berh.2023.101873_bib40","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1136\/annrheumdis-2021-221295","article-title":"Flares after hydroxychloroquine reduction or discontinuation: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort","volume":"81","author":"Almeida-Brasil","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2023.101873_bib41","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1001\/jama.2022.13591","article-title":"Hydroxychloroquine dose per ophthalmology guidelines and the risk of systemic lupus erythematosus flares","volume":"328","author":"Jorge","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.berh.2023.101873_bib42","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1136\/annrheumdis-2022-222435","article-title":"Weaning of maintenance immunosuppressive therapy in lupus nephritis (WIN-Lupus): results of a multicentre randomised controlled trial","volume":"81","author":"Jourde-Chiche","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2023.101873_bib43","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1136\/ard.2006.069039","article-title":"The relationship between cancer and medication exposures in systemic lupus erythaematosus: a case-cohort study","volume":"67","author":"Bernatsky","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2023.101873_bib44","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1002\/acr.24425","article-title":"Cancer risk in a large inception systemic lupus erythematosus cohort: effects of demographic characteristics, smoking, and medications","volume":"73","author":"Bernatsky","year":"2021","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.berh.2023.101873_bib45","doi-asserted-by":"crossref","first-page":"369","DOI":"10.7326\/M19-3369","article-title":"Adverse effects of low-dose methotrexate: a randomized trial","volume":"172","author":"Solomon","year":"2020","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.berh.2023.101873_bib46","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1136\/annrheumdis-2018-213512","article-title":"First Latin American clinical practice guidelines for the treatment of systemic lupus erythematosus: Latin American Group for the Study of Lupus (GLADEL, Grupo Latino Americano de Estudio del Lupus)-Pan-American League of Associations of Rheumatology (PAN","volume":"77","author":"Pons-Estel","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2023.101873_bib47","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1093\/rheumatology\/ker410","article-title":"Glucocorticoid use and abuse in SLE","volume":"51","author":"Ruiz-Irastorza","year":"2012","journal-title":"Rheumatology"},{"key":"10.1016\/j.berh.2023.101873_bib48","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.autrev.2017.05.017","article-title":"Repeated pulses of methyl-prednisolone with reduced doses of prednisone improve the outcome of class III, IV and V lupus nephritis: an observational comparative study of the Lupus-Cruces and lupus-Bordeaux cohorts","volume":"16","author":"Ruiz-Irastorza","year":"2017","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.berh.2023.101873_bib49","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1002\/acr.21664","article-title":"American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis","volume":"64","author":"Hahn","year":"2012","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.berh.2023.101873_bib50","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/rheumatology\/kex286","article-title":"The BSR and BHPR guideline for the management of systemic lupus erythematosus in adults","volume":"57","author":"Gordon","year":"2018","journal-title":"Rheumatology"},{"key":"10.1016\/j.berh.2023.101873_bib51","doi-asserted-by":"crossref","first-page":"S713","DOI":"10.1136\/annrheumdis-2020-216924","article-title":"Update of the joint European League against rheumatism and European renal association-European Dialysis and transplant association (EULAR\/ERA-EDTA) recommendations for the management of lupus nephritis","volume":"79","author":"Fanouriakis","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2023.101873_bib52","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.kint.2021.05.015","article-title":"Executive summary of the KDIGO 2021 guideline for the management of glomerular diseases","volume":"100","author":"Rovin","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/j.berh.2023.101873_bib53","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.autrev.2013.10.013","article-title":"Prednisone in lupus nephritis: how much is enough?","volume":"13","author":"Ruiz-Irastorza","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.berh.2023.101873_bib54","article-title":"EULAR recommendations for the management of systemic lupus erythematosus: 2023 update","author":"Fanouriakis","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2023.101873_bib55","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1136\/annrheumdis-2016-209770","article-title":"EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and\/or antiphospholipid syndrome","volume":"76","author":"Andreoli","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2023.101873_bib56","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/j.ophtha.2016.01.058","article-title":"Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 revision)","volume":"123","author":"Marmor","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.berh.2023.101873_bib57","doi-asserted-by":"crossref","first-page":"V69","DOI":"10.1093\/rheumatology\/keaa403","article-title":"Treating systemic lupus erythematosus in the 21st century: new drugs and new perspectives on old drugs","volume":"59","author":"Ruiz-Irastorza","year":"2021","journal-title":"Rheumatology"},{"key":"10.1016\/j.berh.2023.101873_bib58","first-page":"1","article-title":"Autoinmunes","volume":"2016","author":"Ruiz-Irastorza","year":"2019","journal-title":"Mobile App. Version 1.05. Osakidetza"},{"key":"10.1016\/j.berh.2023.101873_bib59","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1136\/annrheumdis-2019-215571","article-title":"Ultrasensitive serum interferon-\u03b1 quantification during SLE remission identifies patients at risk for relapse","volume":"78","author":"Mathian","year":"2019","journal-title":"Ann Rheum Dis"}],"container-title":["Best Practice &amp; Research Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694223000591?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694223000591?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T15:52:25Z","timestamp":1718812345000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521694223000591"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":59,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["S1521694223000591"],"URL":"https:\/\/doi.org\/10.1016\/j.berh.2023.101873","relation":{},"ISSN":["1521-6942"],"issn-type":[{"value":"1521-6942","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systemic lupus erythematosus and glucocorticoids: A never-ending story?","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Rheumatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.berh.2023.101873","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101873"}}